Farhad Azimi
- Oncology top 10%
- CAR-T cell therapy research 2
- Cancer Immunotherapy and Biomarkers 2
- Cancer Cells and Metastasis 2
- Immunology top 10%
-
- Breast Cancer Treatment Studies 6
- Cancer Genomics and Diagnostics 4
-
- Breast Lesions and Carcinomas 3
-
- Cancer and Skin Lesions 2
-
- Connective tissue disorders research 2
- Co-authors
- Rajmohan MuraliRobyn P.M. SawRichard A. ScolyerMarc MoncrieffJohn F. ThompsonStanley W. McCarthyPatrick J. BryanCarlo Pulitanò
- Cited by
- OncologyImmunologyCancer Research
- Journals
- Annals of Surgical Oncology (4 papers)Clinical Radiology (2 papers)Journal of Clinical Oncology (1 paper)
- Partner nations
- AustraliaUnited StatesGermany
In The Last Decade
Farhad Azimi
15 papers receiving 664 citations
Hit Papers
Peers
Comparison fields: 5 of 58
- Oncology 454
- Immunology 309
- Cancer Research 118
- Pulmonary and Respiratory Medicine 186
- Molecular Biology 224
Countries citing papers authored by Farhad Azimi
This map shows the geographic impact of Farhad Azimi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Farhad Azimi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Farhad Azimi more than expected).
Fields of papers citing papers by Farhad Azimi
This network shows the impact of papers produced by Farhad Azimi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Farhad Azimi. The network helps show where Farhad Azimi may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Farhad Azimi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 4 | |
| 4 | 2024 | 2 | |
| 5 | 2023 | 18 | |
| 6 | 2023 | 1 | |
| 7 | 2023 | 1 | |
| 8 | 2022 | 2 | |
| 9 | 2021 | 0 | |
| 10 | 2021 | 1 | |
| 11 | 2020 | 2 | |
| 12 | 2019 | 15 | |
| 13 | Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanomabreakdown → | 2012 | 606 |
| 14 | 1977 | 3 | |
| 15 | 1974 | 7 | |
| 16 | 1974 | 2 | |
| 17 | 1974 | 5 |
About Farhad Azimi
Farhad Azimi is a scholar working on Cancer Research, Oncology and Dermatology, having authored 17 papers that have together received 671 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (6 papers), Cancer Genomics and Diagnostics (4 papers), Breast Lesions and Carcinomas (3 papers), CAR-T cell therapy research (2 papers), Cancer and Skin Lesions (2 papers), Connective tissue disorders research (2 papers), Cancer Immunotherapy and Biomarkers (2 papers) and Cancer Cells and Metastasis (2 papers). The work is most often cited by research in Oncology (454 citations), Immunology (309 citations) and Cancer Research (118 citations). Farhad Azimi has collaborated with scholars based in Australia, United States and Germany. Frequent co-authors include Rajmohan Murali, Robyn P.M. Saw, Richard A. Scolyer, Marc Moncrieff, John F. Thompson, Stanley W. McCarthy, Patrick J. Bryan, Carlo Pulitanò, Sanjay Warrier and Michael Zhou. Their work appears in journals such as Annals of Surgical Oncology, Clinical Radiology, Journal of Clinical Oncology, British Journal of Radiology and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.